These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37805421)

  • 21. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma.
    Hsu PC; Miao J; Wang YC; Zhang WQ; Yang YL; Wang CW; Yang CT; Huang Z; You J; Xu Z; Jablons DM; You L
    J Cell Mol Med; 2018 Jun; 22(6):3139-3148. PubMed ID: 29575535
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma.
    Kopecka J; Salaroglio IC; Righi L; Libener R; Orecchia S; Grosso F; Milosevic V; Ananthanarayanan P; Ricci L; Capelletto E; Pradotto M; Napoli F; Di Maio M; Novello S; Rubinstein M; Scagliotti GV; Riganti C
    Lung Cancer; 2018 Jun; 120():34-45. PubMed ID: 29748013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification and validation of key genes with prognostic value in non-small-cell lung cancer via integrated bioinformatics analysis.
    Wang L; Qu J; Liang Y; Zhao D; Rehman FU; Qin K; Zhang X
    Thorac Cancer; 2020 Apr; 11(4):851-866. PubMed ID: 32059076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
    Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
    de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
    Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of microRNA expression signatures in malignant pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related targets.
    Ramírez-Salazar EG; Salinas-Silva LC; Vázquez-Manríquez ME; Gayosso-Gómez LV; Negrete-Garcia MC; Ramírez-Rodriguez SL; Chávez R; Zenteno E; Santillán P; Kelly-García J; Ortiz-Quintero B
    Exp Mol Pathol; 2014 Dec; 97(3):375-85. PubMed ID: 25236577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IL-7 is expressed in malignant mesothelioma and has a prognostic value.
    Mai HL; Deshayes S; Nguyen TV; Dehame V; Chéné AL; Brouard S; Blanquart C
    Mol Oncol; 2022 Oct; 16(20):3606-3619. PubMed ID: 36054746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
    Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
    Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High Expression of
    Ma GY; Shi S; Sang YZ; Wang P; Zhang ZG
    Biomed Res Int; 2023; 2023():6575194. PubMed ID: 37139482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
    Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
    Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD157 enhances malignant pleural mesothelioma aggressiveness and predicts poor clinical outcome.
    Ortolan E; Giacomino A; Martinetto F; Morone S; Lo Buono N; Ferrero E; Scagliotti G; Novello S; Orecchia S; Ruffini E; Rapa I; Righi L; Volante M; Funaro A
    Oncotarget; 2014 Aug; 5(15):6191-205. PubMed ID: 25026285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma.
    Nguyen TT; Lee HS; Burt BM; Amos CI; Cheng C
    Br J Cancer; 2022 Nov; 127(9):1691-1700. PubMed ID: 35999269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma.
    Yang H; Berezowska S; Dorn P; Zens P; Chen P; Peng RW; Marti TM; Kocher GJ; Schmid RA; Hall SRR
    Theranostics; 2022; 12(1):167-185. PubMed ID: 34987640
    [No Abstract]   [Full Text] [Related]  

  • 37. A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9-15 PROMISE-meso phase III trial.
    Banna GL; Addeo A; Zygoura P; Tsourti Z; Popat S; Curioni-Fontecedro A; Nadal E; Shah R; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Janthur WD; López-Castro R; Roschitzki-Voser H; Dafni U; Peters S; Stahel RA
    Lung Cancer; 2022 Jul; 169():77-83. PubMed ID: 35660972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Malignant pleural mesothelioma: diagnostic value of medical thoracoscopy and long-term prognostic analysis.
    Xu LL; Yang Y; Wang Z; Wang XJ; Tong ZH; Shi HZ
    BMC Pulm Med; 2018 Apr; 18(1):56. PubMed ID: 29615010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Involvement of the M-CSF/IL-34/CSF-1R pathway in malignant pleural mesothelioma.
    Blondy T; d'Almeida SM; Briolay T; Tabiasco J; Meiller C; Chéné AL; Cellerin L; Deshayes S; Delneste Y; Fonteneau JF; Boisgerault N; Bennouna J; Grégoire M; Jean D; Blanquart C
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Signal Transducer and Activator of Transcription 1 (STAT1) Knock-down Induces Apoptosis in Malignant Pleural Mesothelioma.
    Arzt L; Halbwedl I; Gogg-Kamerer M; Popper HH
    Pathol Oncol Res; 2017 Jul; 23(3):595-605. PubMed ID: 27987139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.